CS
JNCE

Candriam SCA’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Candriam SCA’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-337,398
Closed -$2.82M – 856
2021
Q4 		$2.82M Hold
337,398
– – 0.02% 478
2021
Q3 		$2.51M Hold
337,398
– – 0.02% 535
2021
Q2 		$2.29M Buy
337,398
+337,393
+6,747,860% +$2.8M 0.02% 562
2021
Q1 		$0 Buy
+5
New +$55 ﹤0.01% 823
2020
Q4 		– Sell
-352,760
Closed -$2.88M – 854
2020
Q3 		$2.88M Buy
+352,760
New +$2.19M 0.03% 445
2018
Q3 		– Sell
-25,000
Closed -$192K – 852
2018
Q2 		$192K Buy
+25,000
New +$361K ﹤0.01% 760

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Candriam SCA's JNCE Position: Q1 2022 in Review

Candriam SCA sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 337,398 shares — an estimated $2.82M sold.

Candriam SCA first reported a position in JNCE in Q2 2018 and held it in 6 quarters. The position peaked at $2.88M in Q3 2020. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Candriam SCA reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Candriam SCA sold 337,398 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $2.82M.
  • Candriam SCA first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
  • Candriam SCA's Jounce Therapeutics, Inc. Common Stock position peaked at $2.88M in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Candriam SCA's 13F filing for Q1 2022, filed 13 May 2022.